LLY Is Down 8% After 120 Days. What History Says Now.

Eli Lilly Just Recovered From Its Longest Pullback Since 2024

Eli Lilly and Company (LLY) has officially moved back into the green zone as of May 19, 2026, driven by a 3.25% rally that pushed the stock price to $1021.41. This recovery follows a period of heightened volatility fueled by significant fundamental developments. According to TipRanks, recent reports indicating that President Trump purchased Eli Lilly and Company (LLY) shares coincided with news of government approval for a new weight-loss pill. This regulatory milestone appears to have provided the necessary momentum to lift the stock out of its recent slump.

Assessing the 119-Day Drawdown

As of May 19, 2026, our data shows that Eli Lilly and Company (LLY) has spent 119 days in its current drawdown cycle. This period has been characterized by a move into the yellow zone, a phase where risk levels are typically higher than the historical norm for this specific asset. The stock reached an all-time high of $1109.94 before entering this correction. Currently, the stock sits at a drawdown of -8.0% from that peak.

While an 8.0% decline might seem modest for some high-growth stocks, it is important to view this through the lens of Eli Lilly and Company (LLY)’s historical behavior. Our data tracks 228 total historical drawdown events for this ticker. On average, a typical drawdown for this stock results in a maximum decline of -5.4% and lasts for approximately 62 days. At 119 days, the current cycle has lasted nearly twice as long as the historical average, making this a period of prolonged consolidation rather than a quick dip.

Current Drawdown Severity Score™ and Risk Levels

The most critical metric we monitor is the Drawdown Severity Score™, which currently stands at 1.6 for Eli Lilly and Company (LLY). This score places the stock in the "Slightly Elevated" category, which we define as the green zone. This is a notable shift from the previous yellow zone status, indicating that the immediate selling pressure has abated and the stock is beginning to stabilize relative to its historical risk profile.

The move from the yellow zone back to the green zone suggests that the market is beginning to price in the recent positive news flow reported by Yahoo Finance and Traders Union. Traders Union specifically noted that the stock is currently facing a resistance level near $1,050. Our data confirms that while the Drawdown Severity Score™ has improved, the stock still remains 8.0% below its all-time high. This gap represents the remaining distance the stock must travel to fully erase the current drawdown.

Historical Context: When Drawdowns Turn Deep

To understand the current -8.0% drawdown, we must look at how Eli Lilly and Company (LLY) has handled more severe price contractions in the past. Our records indicate that this stock has experienced drops of 40% or more only 4 times in its entire trading history. This is a relatively small sample size, which is a crucial caveat for investors to consider when evaluating historical averages.

When Eli Lilly and Company (LLY) does enter a major correction of that magnitude, the recovery process is historically slow. The average duration of those comparable drops is 1849 days. While the current 8.0% drawdown is nowhere near those historic 40% collapses, the 119 days already spent in this cycle shows that the stock is currently in a more sluggish recovery phase than its typical 62-day average would suggest.

Is the Recovery Sustainable?

The transition of the Drawdown Severity Score™ from the yellow zone to the green zone is a positive technical signal, but it does not guarantee an immediate return to new highs. Our data shows that Eli Lilly and Company (LLY) has navigated 228 distinct drawdown events, and each one provides a different template for recovery. The current severity score of 1.6 indicates that while the "danger zone" has been exited, the stock is not yet back to a "normal" or "low risk" state.

According to Seeking Alpha, technical analysis suggests that the healthcare sector as a whole is showing signs of strength. This sector-wide tailwind, combined with the specific regulatory approvals for Eli Lilly’s weight-loss pipeline, provides the context for the recent price action. We observe that the stock is currently trading at $1021.41, and the primary objective for a full recovery is a return to the $1109.94 level.

Key Levels and the Drawdown Severity Score™

Investors tracking Eli Lilly and Company (LLY) should focus on whether the Drawdown Severity Score™ can remain within the green zone or if it will regress back into the yellow zone. A regression would indicate that the recent rally was a "dead cat bounce" rather than a true trend reversal. Currently, the stock’s -8.0% drawdown is deeper than its historical average max drawdown of -5.4%, suggesting there is still significant ground to make up.

We will continue to monitor the exact numbers as they evolve. The interaction between the current price of $1021.41 and the historical resistance levels mentioned by market analysts will determine if this 119-day drawdown is nearing its end or if it will extend further. The proprietary Drawdown Severity Score™ remains the most effective tool for filtering out market noise and focusing on the actual risk profile of the stock.